Andy Fenny

Pace®, a science and technology company, has appointed Andrew (Andy) Fenny as President of Pace® Life Sciences, the company’s life sciences division. 

Fenny will lead the division’s next phase of strategic growth, with a focus on expanding support and capacity for pharmaceutical and biotechnology customers across the development lifecycle.

Pharmaceutical and biotechnology companies face growing pressure to accelerate development timelines, navigate scientific and regulatory complexity and manage rising costs. Pace® Life Sciences provides integrated services and scientific solutions designed to help customers address these challenges from early development through clinical supply and commercialization.

Fenny brings more than two decades of experience across the contract development and manufacturing organization (CDMO) and pharmaceutical sectors. He joins Pace® Life Sciences from SK Pharmteco, where he served as Chief Commercial Officer. Previously, he held the position of Chief Business Officer at FUJIFILM Diosynth Biotechnologies.
His experience spans commercial strategy, business development, integrated operations and client experience, positioning him to lead the division’s growth and customer-focused strategy.

Based in Research Triangle Park, North Carolina, Fenny will oversee all aspects of Pace® Life Sciences and strengthen collaboration across its eight sites. He will also direct the delivery of the division’s service capabilities to support customers throughout the drug development and commercialization lifecycle.

Pace® is a portfolio company of Leonard Green & Partners and Aurora Capital Partners.